Insights
Perspectives on Canadian market access for diagnostics and precision medicine companies.
The Drug Is Recommended. The Test Isn't Funded.
Canada already funds MRD where testing is embedded inside provincial laboratory infrastructure. Solid-tumour MRD remains largely outside that system because evidence, drug funding and diagnostic implementation sit in different decision structures.
Market Entry Guide
Seven Structural Mistakes International Diagnostics Companies Make When Entering Canada
A practical guide to the structural assumptions that cause international diagnostics companies to misread Canada's reimbursement, evidence, and provincial adoption pathways.
Read the full article →Capital Allocation Guide
Five Questions to Ask Before Entering the Canadian Diagnostics Market
A boardroom-level guide to the five questions executive teams should answer before committing capital to Canadian diagnostics expansion.
Read the full article →Launch Sequencing
Launch Sequence or Assumption?
If Canada is not explicitly sequenced with capital, evidence, and timeline, it is not a strategy. It is a hope.
Competitive Moat
Can a Canadian Lab Replicate It?
If an academic lab can run a functionally equivalent assay in-house, your commercial model must account for that reality.
Access Pathway
Bridge or Entire Plan?
Out-of-country revenue can open the market, but it is temporary by design unless it becomes a local partnership strategy.
HTA Evidence
Will the Evidence Survive HTA?
FDA clearance and US data are rarely enough. Canadian review requires different evidence, thresholds, and obligations.
Adoption Authority
Who Can Actually Say Yes?
In Canada, oncologist demand is necessary but not sufficient. Lab directors, pathologists, and policy bodies shape adoption.
Strategic guide
How to Choose a Canadian Market Access Partner for Diagnostics
A practical guide to the three partner types in Canadian diagnostics market access, and when founder-led strategic sequencing matters most.
Read the guide →